KRASG12C IN-16

KRASG12C IN-16 (Compound SK-17) is a selective, covalent and an orally active KRASG12C inhibitor. KRASG12C IN-16 induces Apoptosis. KRASG12C IN-16 effectively prevents the activation of MAPK and PI3K/mTOR signaling pathways. KRASG12C IN-16 displays anti-tumor activity against pancreatic cancer[1].

Product Specifications

UNSPSC

12352005

Target

Apoptosis; mTOR; p38 MAPK; PI3K; Ras

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; PI3K/Akt/mTOR

Field of Research

Cancer

Smiles

ClC1=C(C(NC(N2CC3=NC(N4CC(C4)N(C)C)=NC(N5C6CN(CC5CC6)C(C=C)=O)=C3C2)=O)=CC=C1)C

Molecular Formula

C28H35ClN8O2

Molecular Weight

551.08

References & Citations

[1]Fu S, et al. Design, Synthesis and Biological Evaluation of Pyrrolopyrimidine Urea Derivatives as Novel Krasg12c Inhibitors for the Treatment of Cancer.